BioAge Labs Inc.
(NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting therapies.
William Blair analyst Andy Hsieh said the results from Novo Nordisk's ZEUS trial cast doubt on the link between large reductions in high-sensitivity C-reactive protein (hsCRP) and protection against major adverse cardiovascular events (MACE).
Novo Nordisk Trial Raises Questions For BioAge Novo Nordisk said Friday that its experimental drug ziltivekimab failed to reduce the risk of major adverse cardiovascular events versus placebo in high-risk patients in the Phase 3 ZEUS trial.
Hsieh noted that Novo Nordisk did not disclose the numerical hsCRP reduction in the study.
